Building Bridges: Purposeful Networking, Collaboration, and Career Growth with Industry Relationships
Working with industry is a common career goal of dermatologists, whether it’s by serving on an advisory board, obtaining a grant, or collaborating in another way. So how does a dermatologist land these industry opportunities? Watch as Dr. Adam Friedman, co-chair of the ODAC Dermatology Conference, outlines how to build bridges with industry partners. Find out why it’s important to understand t …
Working with industry is a common career goal of dermatologists, whether it’s by serving on an advisory board, obtaining a grant, or collaborating in another way. So how does a dermatologist land these industry opportunities? Watch as Dr. Adam Friedman, co-chair of the ODAC Dermatology Conference, outlines how to build bridges with industry partners. Find out why it’s important to understand t … 
The February 2025 issue of the Journal of Drugs in Dermatology brings a fresh wave of clinical insights and innovative research to the dermatology community. This edition highlights new perspectives on minoxidil adherence, groundbreaking findings in keloid and hypertrophic scar risk factors, and expert consensus on deucravacitinib for plaque psoriasis.
Readers will also discover updates on non- … 
At the 2025 ODAC Dermatology Conference, renowned dermatologist and conference co-chair Adam Friedman, MD, delivered an insightful lecture, How I Treat Rosacea in 2025. He explored the latest advancements in managing one of dermatology’s most prevalent conditions, highlighting key triggers, associated comorbidities, and evolving treatment strategies. With global rosacea prevalence reported as hi … 
Underrepresentation of patients with skin of color in clinical trials is an issue in medical research, including in research about dermatological conditions. A study in the January Journal of Drugs in Dermatology looked at the diversity of patients enrolled in melasma clinical trials to determine if there are any disparities in representation.
I interviewed author Jared Jagdeo, MD, MS, associat … 
At the forefront of the evolving treatment landscape for cutaneous squamous cell carcinoma (cSCC), Dr. David M. Miller—a board-certified internist, dermatologist, and medical oncologist at Massachusetts General Hospital—delivered a highly informative lecture on the past, present, and future of immunotherapy for cSCC at ODAC 2025. With his unique expertise across three disciplines, Dr. Miller e … 